Organon stock presents new VTAMA analysis ahead of November results

Published on 10/04/2026 at 19:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Organon stock was last at USD 13.72 on October 2, while Zacks sees Q3 EPS at USD 0.91. Q2 revenue fell 2.3 percent to USD 1.56 billion.

OGN, US68622V1061, Illustration mit AI erstellt.

Organon stock was last at USD 13.72 on the NYSE on October 2, 2026, with a market capitalization of USD 3.6 billion and a 52-week range of USD 5.69 to USD 13.79. The company’s latest product update came on October 1, when Business Wire reported that Organon would present new real-world analysis of VTAMA cream at the 2026 Fall Clinical Dermatology Conference.

VTAMA adds a clinical checkpoint

The analysis covers patients with atopic dermatitis treated with tapinarof cream, including physician-reported outcomes for body surface area and global assessment as well as patient-reported itch scores. The October 1, 2026, update gives investors a concrete pipeline and commercialization checkpoint while the stock remains only USD 0.07 below its 52-week high.

Organon’s recent product activity also includes MIUDELLA, a hormone-free intrauterine device accepted for US FDA review on September 14, 2026, according to the company’s investor-relations page. That regulatory milestone and the VTAMA presentation place women’s health and specialty medicines at the center of the current company narrative.

Q2 revenue fell 2.3 percent

In Q2 2026, Organon reported revenue of USD 1.56 billion, down 2.3 percent year over year, while EPS was USD 0.85 versus USD 1.00 in the year-ago quarter, according to Zacks. Revenue exceeded the USD 1.54 billion consensus estimate by 1.09 percent, but the EPS result missed consensus by 2.3 percent.

The forward picture is mixed in precise terms. Zacks cites a current-quarter EPS consensus of USD 0.91, a year-over-year decline of 9.9 percent, and a sales estimate of USD 1.57 billion, down 2 percent from the comparable period.

Analyst target stays below the stock

MarketBeat reported on September 18, 2026, that seven research firms carried a Reduce consensus, with two Sell ratings and five Hold ratings. The average 12-month price target was USD 11.40, USD 2.32 below the October 2 price.

That gap makes the next earnings update important for the valuation debate. GetSignal lists November 9, 2026, as the next earnings date and shows Q2 2026 EPS of USD 0.85 against USD 0.85 expected, with revenue of USD 1.6 billion against USD 1.6 billion expected.

OGN remains near its yearly high

Organon was last at USD 13.72 on the NYSE on October 2, 2026, with a daily change of 0.07 percent and volume of 1,921,134 shares. The stock stood 0.51 percent below its 52-week high of USD 13.79, leaving clinical updates, quarterly execution and the USD 11.40 consensus target as the main figures for investors weighing the current valuation.